Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers ACLX GILD
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces First Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD XLO
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.